Sunday, May 9, 2021
Google search engine
HomeLatest NewsWORLD NEWS SUPERFAST - DAILY NEWS HEADLINES

WORLD NEWS SUPERFAST – DAILY NEWS HEADLINES


WORLD NEWS SUPERFAST

India News – Zydus says 91.15 per cent
of patients treated with PegIFN were RT-PCR negative by day 7. The treatment
significantly reduces the hours of supplemental oxygen in the patients.
Zydus
Cadila on Friday announced that it has received restricted emergency use
approval

from the Indian drug regulator,
Drug Controller General of India (DCGI), for the use of ‘Virafin Pegylated
Interferon alpha-2b (PegIFN) in treating moderate Covid19
 infection in adults.


The approval follows promising results from a late-stage study of the drug, and
comes in the middle of a massive wave of COVID-19 cases in India, which has
overwhelmed its health system and left many hospitals short of critical oxygen
supplies.

A single dose subcutaneous
regimen of the antiviral Virafin will make the treatment more convenient for
the patients. When administered early on during Covid, Virafin will help
patients recover faster and avoid much of the complications. Virafin will be
available on the prescription of medical specialist for use in
hospital/institutional setup, the company said in a filing.

Cadila Healthcare’s stock rose sharply
after getting the emergency use nod. On Friday, the stock ended trading 3.4%
higher on NSE.

Pegylated Interferon alpha-2b was
originally approved for liver disease Hepatitis C and launched in India 10
years ago. It is being repurposed to treat Covid-19.

In the multicentric trial
conducted in 20-25 centers across India, Zydus said Virafin had shown lesser
need for supplemental oxygen, “clearly indicating that it was able to
control respiratory distress and failure which has been one of the major challenges
in treating Covid-19.”

Zydus said the drug has also
shown efficacy against other viral infections

Speaking on the development,
Sharvil Patel, Managing Director of Cadila Healthcare said, “The fact that we
are able to offer a therapy which significantly reduces viral load when given
early on can help in better disease management. It comes at a much-needed time
for patients and we will continue to provide them access to critical therapies
in this battle against Covid-19.”

In its Phase-3 clinical trials,
the therapy had shown better clinical improvement in the patients suffering
from Covid-19

“During the trials, a higher
proportion of patients administered with PegIFN arm were RT PCR negative by day
7. The drug ensures faster viral clearance and has several add-on advantages
compared to other anti-viral agents,” the company said.



Source link

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -
Google search engine

Most Popular

Recent Comments